US Stock Insider Trading | Recursion disclosed 3 insider transactions on February 10

K-LinePoet · 2026-02-11T22:06:48+00:00

Recursion disclosed multiple insider transactions by executives and directors on February 6, 2026, including Taylor Ben R and Hallett David selling 11,400 shares each, and Khan Najat selling 10,400 shares. The company's business focuses on bio-decoding technology to advance the commercialization of drug discovery.

K-LinePoet

2026-02-11 22:06:48

Abstract generation in progress

On February 10, 2026, Recursion (RXRX) disclosed three insider trading transactions. Executive Taylor Ben R sold 11,400 shares on February 6, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 10, 2026	Executive	Taylor Ben R	February 6, 2026	Sell	11,400	3.98	45,400
February 10, 2026	Executive	Hallett David	February 6, 2026	Sell	11,400	3.98	45,400
February 10, 2026	Director	Khan Najat	February 6, 2026	Sell	10,400	3.98	41,200
February 6, 2026	Director	Borgeson Blake	February 3, 2026	Sell	220,000	4.20	924,000
February 6, 2026	Director	Gibson Christopher	February 4, 2026	Sell	40,000	4.12	164,800
February 6, 2026	Director	Gibson Christopher	February 6, 2026	Sell	10,400	3.56	36,900
January 22, 2026	Director	Gibson Christopher	January 20, 2026	Sell	40,000	4.47	178,800
January 8, 2026	Director	Borgeson Blake	January 6, 2026	Sell	220,000	4.36	959,200
January 7, 2026	Director	Gibson Christopher	January 5, 2026	Sell	40,000	4.25	170,000
December 30, 2025	Executive	Taylor Ben R	December 29, 2025	Sell	21,400	4.18	89,400

[Company Information]

Recursion Pharmaceuticals, Inc. was originally founded on November 4, 2013, and incorporated in Delaware. The company is a leading clinical-stage TechBio firm that decodes biology to industrialize drug discovery. The core of the company’s mission is the Recursive Operating System (OS), a platform built across multiple technologies that enables the company to map and navigate trillions of biologically, chemically, and patient-centered relationships within over 50 PB of proprietary data. The company frames this integration of physical and digital components as an iterative cycle, where scaled “wet lab” biological, chemical, and patient-centered experimental data are organized by “dry lab” computational tools to identify, validate, and translate therapeutic insights.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.